🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Chronic Obstructive Pulmonary Disease Severe

Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease NCT06531798Phase 46 sites📍 Bangalore📍 Dalgate, Drugjan📍 Hyderabad AstraZeneca · Tests: Breztri Aerosphere Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation NCT06959095Phase 3281 sites📍 Bakersfield📍 Modesto📍 Newport Beach GlaxoSmithKline · Tests: Depemokimab, Placebo A Trial of the Implantable Artificial Bronchus 50 Flex in Patients With Severe Emphysema NCT07086339NA2 sites📍 Limoges📍 Groningen Pulmair Medical, Inc. · Tests: Implantable pulmonary stent Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo NCT07069829n/a36 sites📍 Buenos Aires📍 La Plata📍 Mar del Plata AstraZeneca A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK) NCT07116031Phase 235 sites📍 Los Angeles📍 Washington D.C.📍 Atlanta Sanofi · Tests: Belumosudil, Belumosudil A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) NCT07759245Phase 2127 sites📍 Birmingham📍 Newport Beach📍 San Diego Eli Lilly and Company · Tests: Brenipatide, Placebo, Standard of Care A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease NCT07082738Phase 2367 sites📍 Birmingham📍 Glendale📍 Phoenix AstraZeneca · Tests: AZD6793, Placebo A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema NCT06152107NA9 sites📍 Zhengzhou📍 Beijing📍 Chengdu Shanghai Chest Hospital · Tests: BTVA treatment plus optimal medical therapy (GOLD guidelines) This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization NCT07587658Phase 41 site📍 Mullica Hill Regeneron Pharmaceuticals · Tests: dupilumab, Placebo 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation NCT07192016Phase 41 site📍 London Western University, Canada · Tests: fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) NCT06961214Phase 3193 sites📍 Sheffield📍 Aurora📍 Brooksville GlaxoSmithKline · Tests: Depemokimab, Placebo A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis NCT07725939Phase 213 sites📍 Miami📍 Rincon📍 Columbus UCB Biopharma SRL · Tests: Galvokimig, Placebo Risk Prediction Model for Exacerbating Phenotype in Patients With Chronic Obstructive Pulmonary Disease NCT06198309n/a1 site📍 Beijing Li An CLEAR Model for Predicting Ventilatory Liberation in Severe COPD NCT07579052n/a1 site📍 Asyut Assiut University A Clinical Study of Inhaled Nitric Oxide in Moderate-to-Severe Chronic Obstructive Pulmonary Disease NCT05896800NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Inhaled nitric oxide (NO), air Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury NCT05951777Phase 22 sites📍 Houston📍 San Antonio Hope Biosciences LLC · Tests: Autologous HB-adMSCs, Normal Saline A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) NCT06883305Phase 3305 sites📍 Foley📍 Mobile📍 Sheffield AstraZeneca · Tests: Tezepelumab, Placebo An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema NCT06035120NA38 sites📍 Phoenix📍 Loveland📍 Hartford Pulmonx Corporation · Tests: AeriSeal System Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease NCT06072690n/a1 site📍 Kaunas Lithuanian University of Health Sciences Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells NCT06491043Phase 22 sites📍 New Taipei City📍 Taoyuan City Meribank Biotech Co., Ltd. · Tests: UMC119-06-05 Zephyr Valve Japan Post-Marketing Surveillance NCT06332885n/a17 sites📍 Aichi📍 Gifu📍 Kanagawa Pulmonx Corporation · Tests: Zephyr Endobronchial Valve Prospective and Multicentric Cohort Study of Severe and Very Severe Chronic Obstructive Pulmonary Disease (COPD) in Brazil (SCOPe). NCT06724315n/a1 site📍 São Paulo Hospital Israelita Albert Einstein Acute Effect of Different Frequency of Whole Body Vibration (WBV) on Healthy and Chronic Obstructive Pulmonary Disease (COPD) NCT07509606NA1 site📍 Tainan National Cheng Kung University · Tests: Whole body vibration A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1) NCT07780669Phase 32 sites📍 Doral📍 Lake Charles GlaxoSmithKline · Tests: GSK5784283, Placebo, Standard of care A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD NCT07668518Phase 1, Phase 23 sites📍 Charlestown📍 Sydney📍 Camberwell Kither Biotech Srl · Tests: KIT2014, Placebo A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) NCT06878261Phase 3284 sites📍 Birmingham📍 Cullman📍 Phoenix AstraZeneca · Tests: Tezepelumab, Placebo A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease NCT07640451Phase 21 site📍 Shanghai Guangdong Hengrui Pharmaceutical Co., Ltd · Tests: HRS-9821 Inhalation Suspension, HRS-9821 Placebo Inhalation Suspension Phase II Study of RC1416 Injection in COPD NCT07402551Phase 246 sites📍 Hefei📍 Suzhou📍 Chongqing Nanjing RegeneCore Biotech Co., Ltd. · Tests: RC1416, RC1416 Placebo Cell Therapy Associated With Endobronchial Valve NCT04018729Phase 2, Phase 31 site📍 Porto Alegre Hospital de Clinicas de Porto Alegre · Tests: Zephyr Endobronchial Valve, Marrow-derived mesenchymal stromal cell Deployment o the Multidisciplinary Prospective Cohort Imminent NCT04334031NA1 site📍 Lille University Hospital, Lille · Tests: Biobanking with genetic analysis, SF-12 questionnaire
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy